International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
OBJECTIVE
To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group.


METHODS
In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized.


RESULTS
Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation.


CONCLUSIONS
New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.
Lokhorst
Henk
H
Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands. h.lokhorst@umcutrecht.nl
Einsele
Hermann
H
Vesole
David
D
Bruno
Benedetto
B
San Miguel
Jesus
J
Pérez-Simon
Jose A
JA
Kröger
Nicolaus
N
Moreau
Philippe
P
Gahrton
Gosta
G
Gasparetto
Cristina
C
Giralt
Sergio
S
Bensinger
William
W
D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009101:Multiple Myeloma / Q000601:surgery*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous